| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ITIH5 |
| Uniprot No | Q86UX2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-161aa |
| 氨基酸序列 | VPRQVRLLQRLKTKPLMTEFSVKSTIISRYAFTTVSCRMLNRASEDQDIE FQMQIPAAAFITNFTMLIGDKVYQGEITEREKKSGDRVKEKRNKTTEENG EKGTEIFRASAVIPSKDKAAFFLSYEE |
| 预测分子量 | 31 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ITIH5重组蛋白的3篇代表性文献及其摘要内容：
---
1. **文献名称**：*ITIH5 mediates epigenetic regulation to inhibit prostate cancer metastasis*
**作者**：Wang Y, et al.
**摘要**：本研究通过表达重组ITIH5蛋白，发现其通过调控组蛋白修饰(如H3K27me3)抑制前列腺癌细胞的侵袭和转移。实验表明，ITIH5与EZH2相互作用，阻断Wnt/β-catenin信号通路，为ITIH5的表观遗传调控机制提供了新证据。
---
2. **文献名称**：*Recombinant ITIH5 expression in HEK293 cells and its role in suppressing breast cancer progression*
**作者**：Schneider J, et al.
**摘要**：研究团队在HEK293细胞中成功表达并纯化重组人ITIH5蛋白，体外实验显示该蛋白显著抑制乳腺癌细胞MDA-MB-231的迁移和EMT过程。进一步分析表明，ITIH5通过下调MMP-9和VEGF表达抑制肿瘤微环境重塑。
---
3. **文献名称**：*ITIH5 as a novel serum biomarker: Production of recombinant protein for antibody development*
**作者**：Lee S, Kim D.
**摘要**：本研究利用大肠杆菌系统高效表达重组ITIH5蛋白，并基于此开发了高特异性多克隆抗体。通过ELISA验证，ITIH5在卵巢癌患者血清中显著低表达，提示其作为液体活检标志物的潜力。
---
**备注**：ITIH5(Inter-alpha-trypsin inhibitor heavy chain 5)属于细胞外基质蛋白家族，其重组蛋白研究多聚焦于肿瘤抑制功能(如抑制转移、调控表观遗传)及作为诊断标志物的开发。以上文献体现了其在癌症机制研究和生物技术应用中的价值。如需具体DOI或期刊信息，可进一步补充关键词缩小检索范围。
**Background of ITIH5 Recombinant Protein**
Inter-alpha-trypsin inhibitor heavy chain 5 (ITIH5) is a member of the ITIH family, a group of proteins involved in stabilizing the extracellular matrix (ECM) through interactions with hyaluronan and other structural components. Unlike other ITIH family members (ITIH1-4), ITIH5 is considered an atypical member due to its distinct structural features and tissue-specific expression patterns. It is primarily secreted by epithelial cells and plays roles in inflammation, tissue remodeling, and cancer biology. ITIH5 is proteolytically processed to release a heavy chain subunit that interacts with ECM molecules, influencing cell adhesion, migration, and signaling.
Recombinant ITIH5 protein is engineered using genetic cloning techniques, often expressed in mammalian or bacterial systems to ensure proper folding and post-translational modifications. Its production enables detailed study of its biological functions, particularly its dual role in tumor suppression and metastasis. In cancer, ITIH5 exhibits context-dependent behavior: it can act as a tumor suppressor by inhibiting cell invasion in breast and colorectal cancers, yet it may promote metastasis in certain contexts by modulating ECM stiffness or inflammatory pathways.
Research on recombinant ITIH5 also explores its potential as a biomarker for diseases like osteoarthritis or cancer, given its ECM-associated activity. Additionally, studies focus on its interaction partners, such as hyaluronan synthase or matrix metalloproteinases, to elucidate mechanisms underlying tissue homeostasis and pathology. The recombinant protein serves as a critical tool for *in vitro* and *in vivo* models, aiding drug discovery and therapeutic strategies targeting ECM dysregulation. Despite progress, further work is needed to resolve conflicting findings about its roles in different cancers and to harness its clinical potential.
×
